false 0001603207 0001603207 2024-04-09 2024-04-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, DC 20549





Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 9, 2024



(Exact name of registrant as specified in charter)



Israel   001-36581   Not Applicable

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


320 Hatch Drive    
Foster City, California   94404
(Address of principal executive offices)   (Zip Code)



Registrant’s telephone number, including area code: (415) 851-2410



(Former name or former address, if changed since last report)


Securities registered or to be registered pursuant to Section 12(b) of the Act:


Title of each class  

Trading Symbol(s)

  Name of each exchange on which registered
Ordinary Shares, par value NIS 0.35 each   NTBL   The Nasdaq Capital Market


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐






Item 8.01 Other Events.


On April 9, 2024, Notable Labs, Ltd. (the “Company”) issued a press release regarding the presentation, at the American Association for Cancer Research (AACR 2024) conference being held in San Diego, California, of the design plan for the Company’s Predictive Precision Medicine Platform (PPMP)-Enabled Phase 2 Trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). A copy of the press release is filed herewith as Exhibit 99.1.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


99.1   Press Release issued April 9, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 9, 2024 By: /s/ Thomas A. Bock
    Name: Thomas A. Bock
    Title: Chief Executive Officer



EX-99.1 2 ex99-1.htm


Exhibit 99.1



Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024


Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a proof-of-concept study using 41 primary acute myeloid leukemia (AML) samples
Plans to incorporate a dose optimization prelude to enhance patient response and tolerability also outlined in the poster


FOSTER CITY, CA, April 9, 2024 – Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).


“We are very pleased to share more data regarding our clinical program and proprietary platform with the oncology community at AACR 2024. Presenting a summary of the Phase 2 volasertib study design in AML provides us with an opportunity to highlight the potential for the PPMP to effectively predict responders, and enroll an responder-enriched patient population, in our upcoming clinical program. Our clinical program will incorporate the co-development of a companion diagnostic test,” said Thomas Bock, M.D., Chief Executive Officer of Notable.


Joseph Wagner, Ph.D., Chief Scientific Officer of Notable, commented, “The abstract highlights technical features of volasertib on Notable’s PPMP, including our method to develop a companion diagnostic test and define a cut-off value to predict responders. Based on the robust results of a 41-sample proof-of-concept study summarized in the poster, we are optimistic about the potential for PPMP to improve patient selection and lead to a strong Phase 2 study. In addition, we look forward to implementing a dosing optimization plan, including standardized use of best supportive care and introduction of body surface area-based dosing, to enhance patient responses and tolerability.”


Poster Highlights:


Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients


Overview: While prior studies of volasertib demonstrated an approximately 30% complete response/complete response with incomplete count recovery (CR/CRi) rate in de novo AML patients in combination with cytarabine, development was halted in part due to toxicity potentially related to the use of a flat dose, rather than patient-specific, body-surface area (BSA) dosing. Notable Labs provided an updated plan for the design of an open label Phase 2 study, including a dose optimization plan aimed at reducing toxicity while maintaining efficacy and an overview of study objectives and endpoints. As part of the study, a companion diagnostic assay to predict responders will be co-developed utilizing the Company’s proprietary flow-cytometry-based PPMP.





Method: Ex vivo flow cytometry experiments evaluated the treatment of volasertib on 41 primary acute myeloid leukemia (AML) samples collected from peripheral blood or bone marrow. Dose-response profiles consistent with volasertib’s role as a cell cycle inhibitor were observed. To obtain a preliminary concentration of volasertib for patient stratification, Notable compared the ex vivo resistant blast fractions (leukemic cells surviving ex vivo treatment with volasertib) at several concentrations with the areas under the volasertib dose-response curves (AUCs), assuming that AUCs would correspond most accurately with the clinical responses.


Results: The results suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to stratify patients into responders and non-responders. These preliminary metrics predict that 32-33% of de novo patients and 25% of R/R AML patients would be predicted to be responders if they were treated with volasertib.


Poster information:


Session Category: Clinical Research
Session Title: Predictive Biomarkers
Session Date and Time: Tuesday Apr 9, 2024, 9:00 AM - 12:30 PM PT
Location: Poster Section 45
Poster Board Number: 19
Published Abstract Number: 5178


The full poster will be posted to the company’s website in the Scientific Presentations & Publications page in the News section of the website shortly after the event.


About Volasertib


Volasertib is a PLK-1 inhibitor with demonstrated activity in AML and other tumor types, including solid tumors, with significant unmet medical need. Building on the performance of volasertib on PPMP, an important and proprietary step during Notable’s targeted in-licensing strategy and decision making, Notable will utilize PPMP to predict volasertib-responsive patients prior to their treatment, with the goal of selectively enrolling and treating those predicted responders, increasing volasertib’s response rates and overall patient outcomes, and fast-tracking volasertib’s remaining clinical development in this patient population. Volasertib was originally developed and manufactured by Boehringer Ingelheim and previously granted breakthrough therapy designation by the FDA. Notable in-licensed volasertib and obtained exclusive worldwide development and commercialization rights, except for certain rare pediatric cancers.


About Notable Labs, Ltd.


Notable Labs, Ltd. Is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable aims to predict whether or not a patient is likely to respond to a specific therapeutic. The PPMP is designed to identify and select clinically responsive patients prior to their treatment, potentially fast-tracking clinical development. By continually advancing and expanding the reach of the PPMP across diseases and predicted medical outcomes, Notable aims to be the leader in predictive precision medicine and revolutionize the way patients seek and receive treatments that work best for them.


Notable believes it has created a targeted and de-risked in-licensing strategy to deliver a product’s medical impact and commercial value faster, with a greater likelihood of success, than traditional drug development. By transforming historical standards of care, Notable aims to create a dramatically positive impact for patients and the healthcare community. Notable is headquartered in Foster City, California. Learn more at our website and follow us @notablelabs.





Forward Looking Statements


This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding Notable’s future operations and goals; the potential benefits of any therapeutic candidates or platform technologies of Notable; the timing of any clinical milestones of Notable’s therapeutic candidates; the cash runway of the company; and other statements that are not historical fact. All statements other than statements of historical fact contained in this communication are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and are based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Notable’s control. Notable’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) uncertainties associated with Notable’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (ii) risks related to the inability of Notable to obtain sufficient additional capital to continue to advance these product candidates and any preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) risks associated with Notable’s future financial and operating results, including its ability to become profitable; (vi) Notable’s ability to retain key personnel; (vii) Notable’s ability to manage the requirements of being a public company; (viii) uncertainties relating to the Israel-Hamas war; (ix) Notable’s ability to obtain orphan drug designation, and the associated benefits, for any of its drug candidates; (x) Notable’s inability to obtain regulatory approval for any of its drug candidates; and (xi) changes in, or additions to international, federal, state or local legislative requirements, such as changes in or additions to tax laws or rates, pharmaceutical regulations, and other regulations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (“SEC”), including the factors described in the section titled “Risk Factors” in the Quarterly Report on Form 10-Q of Notable Labs, Ltd. as filed with the SEC on November 14, 2023, and in other subsequent filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Notable expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.



Investor Relations:

Daniel Ferry, LifeSci Advisors

+1 (617) 430-7576





GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 ntbl-20240409.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ntbl-20240409_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ntbl-20240409_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Apr. 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 09, 2024
Entity File Number 001-36581
Entity Registrant Name NOTABLE LABS, LTD.
Entity Central Index Key 0001603207
Entity Incorporation, State or Country Code L3
Entity Address, Address Line One 320 Hatch Drive
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code (415)
Local Phone Number 851-2410
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value NIS 0.35 each
Trading Symbol NTBL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://notablelabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. form8-k.htm form8-k.htm ntbl-20240409.xsd ntbl-20240409_lab.xml ntbl-20240409_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "NTBL", "nsuri": "http://notablelabs.com/20240409", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ntbl-20240409.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ntbl-20240409_lab.xml" ] }, "presentationLink": { "local": [ "ntbl-20240409_pre.xml" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "report": { "R1": { "role": "http://notablelabs.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://notablelabs.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-014100-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-014100-xbrl.zip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end XML 19 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001603207 2024-04-09 2024-04-09 iso4217:USD shares iso4217:USD shares false 0001603207 8-K 2024-04-09 NOTABLE LABS, LTD. L3 001-36581 320 Hatch Drive Foster City CA 94404 (415) 851-2410 Ordinary Shares, par value NIS 0.35 each NTBL NASDAQ false false false false false